The Matrix Metalloproteinase 9 Point-of-Care Test in Dry Eye.

[1]  S. Joachim,et al.  Correlation of Tear Film Osmolarity and 2 Different MMP-9 Tests With Common Dry Eye Tests in a Cohort of Non–Dry Eye Patients , 2015, Cornea.

[2]  A. Galor,et al.  Dry Eye Profiles in Patients with a Positive Elevated Surface Matrix Metalloproteinase 9 Point-of-Care Test Versus Negative Patients. , 2015, The ocular surface.

[3]  S. Tauber,et al.  Prospective, Multicenter, Clinical Evaluation of Point-of-Care Matrix Metalloproteinase-9 Test for Confirming Dry Eye Disease , 2014, Cornea.

[4]  E. Akpek,et al.  Dry Eye: an Inflammatory Ocular Disease , 2014, Journal of ophthalmic & vision research.

[5]  J. Durán,et al.  Tear MMP-9 levels as a marker of ocular surface inflammation in conjunctivochalasis. , 2013, Investigative ophthalmology & visual science.

[6]  B. Holden,et al.  Effect of Contact Lens Wear on the Diurnal Profile of Matrix Metalloproteinase 9 in Tears , 2013, Optometry and vision science : official publication of the American Academy of Optometry.

[7]  Chih‐Chung Lin,et al.  IL-1β Promotes Corneal Epithelial Cell Migration by Increasing MMP-9 Expression through NF-κB- and AP-1-Dependent Pathways , 2013, PloS one.

[8]  C. Luchinat,et al.  A Highly Soluble Matrix Metalloproteinase‐9 Inhibitor for Potential Treatment of Dry Eye Syndrome , 2012, Basic & clinical pharmacology & toxicology.

[9]  K. Ward,et al.  Correlation of tear inflammatory cytokines and matrix metalloproteinases with four dry eye diagnostic tests. , 2012, Investigative ophthalmology & visual science.

[10]  R. Dana,et al.  Dry eye disease: an immune-mediated ocular surface disorder. , 2012, Archives of ophthalmology.

[11]  T. O'brien,et al.  MMP-9 and the perioperative management of LASIK surgery , 2011, Current opinion in ophthalmology.

[12]  K. Ward,et al.  A method to extract cytokines and matrix metalloproteinases from Schirmer strips and analyze using Luminex , 2011, Molecular vision.

[13]  İ. Can,et al.  Topical Cyclosporine in Thyroid Orbitopathy-Related Dry Eye: Clinical Findings, Conjunctival Epithelial Apoptosis, and MMP-9 Expression , 2010, Current eye research.

[14]  R. Bischoff,et al.  Physiology and pathophysiology of matrix metalloproteases , 2010, Amino Acids.

[15]  N. Friedman,et al.  Impact of dry eye disease and treatment on quality of life , 2010, Current opinion in ophthalmology.

[16]  M. Araie,et al.  Effect of latanoprost on the expression of matrix metalloproteinases and tissue inhibitor of metalloproteinase 1 on the ocular surface. , 2010, Archives of ophthalmology.

[17]  H. Hsieh,et al.  IL-1 beta promotes A549 cell migration via MAPKs/AP-1- and NF-kappaB-dependent matrix metalloproteinase-9 expression. , 2009, Cellular signalling.

[18]  Srihari Narayanan,et al.  Advancements in anti-inflammatory therapy for dry eye syndrome. , 2009, Optometry.

[19]  De-Quan Li,et al.  Production and activity of matrix metalloproteinase-9 on the ocular surface increase in dysfunctional tear syndrome. , 2009, Investigative ophthalmology & visual science.

[20]  T. Sobrino,et al.  Subclinical keratoconus and inflammatory molecules from tears , 2009, British Journal of Ophthalmology.

[21]  E. Sen,et al.  Comparison of the Effects of Latanoprost and Bimatoprost on Central Corneal Thickness , 2008, Journal of glaucoma.

[22]  Carolyn G. Begley,et al.  The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007). , 2007, The ocular surface.

[23]  Christophe Baudouin,et al.  The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). , 2007, The ocular surface.

[24]  Lee Stern,et al.  Dysfunctional Tear Syndrome: A Delphi Approach to Treatment Recommendations , 2006, Cornea.

[25]  De-Quan Li,et al.  Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. , 2006, Experimental eye research.

[26]  De-Quan Li,et al.  Desiccating stress stimulates expression of matrix metalloproteinases by the corneal epithelium. , 2006, Investigative ophthalmology & visual science.

[27]  D. Zoukhri.  Effect of inflammation on lacrimal gland function. , 2006, Experimental eye research.

[28]  De-Quan Li,et al.  Hyperosmolar Saline Is a Proinflammatory Stress on the Mouse Ocular Surface , 2005, Eye & contact lens.

[29]  De-Quan Li,et al.  Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. , 2004, Investigative ophthalmology & visual science.

[30]  Jason J Nichols,et al.  The Lack of Association Between Signs and Symptoms in Patients With Dry Eye Disease , 2004, Cornea.

[31]  J. Chodosh,et al.  A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. , 2004, American journal of ophthalmology.

[32]  Karla Zadnik,et al.  The Repeatability of Clinical Measurements of Dry Eye , 2004, Cornea.

[33]  P. Brun,et al.  Tear levels and activity of matrix metalloproteinase (MMP)-1 and MMP-9 in vernal keratoconjunctivitis. , 2003, Investigative ophthalmology & visual science.

[34]  K. Fukuda,et al.  Active matrix metalloproteinases in the tear fluid of individuals with vernal keratoconjunctivitis. , 2002, The Journal of allergy and clinical immunology.

[35]  A. Solomon,et al.  Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. , 2001, Investigative ophthalmology & visual science.

[36]  A. Solomon,et al.  Treatment of recalcitrant recurrent corneal erosions with inhibitors of matrix metalloproteinase-9, doxycycline and corticosteroids. , 2001, American journal of ophthalmology.

[37]  I. Gipson,et al.  Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. , 2000, Archives of ophthalmology.

[38]  S. Pflugfelder,et al.  A standardized visual scale for evaluation of tear fluorescein clearance. , 2000, Ophthalmology.

[39]  L. Sobrin,et al.  Regulation of MMP-9 activity in human tear fluid and corneal epithelial culture supernatant. , 2000, Investigative ophthalmology & visual science.

[40]  B. Reis,et al.  Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease1 , 2000 .

[41]  S. Pflugfelder,et al.  Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjögren's syndrome keratoconjunctivitis sicca. , 1999, Current eye research.

[42]  K. Barton,et al.  Inflammatory cytokines in the tears of patients with ocular rosacea. , 1997, Ophthalmology.

[43]  H. D. Cavanagh,et al.  Rapid Assay of Lactoferrin in Keratoconjunctivitis Sicca , 1994, Cornea.

[44]  Pasquale Aragona,et al.  Matrix metalloproteinase 9 and transglutaminase 2 expression at the ocular surface in patients with different forms of dry eye disease. , 2015, Ophthalmology.

[45]  S. Tauber,et al.  Sensitivity and specificity of a point-of-care matrix metalloproteinase 9 immunoassay for diagnosing inflammation related to dry eye. , 2013, JAMA ophthalmology.

[46]  D. Borsook,et al.  The corneal pain system. Part I: the missing piece of the dry eye puzzle. , 2012, The ocular surface.

[47]  G. Foulks.  Topical Cyclosporine for Treatment of Ocular Surface Disease , 2006, International ophthalmology clinics.

[48]  M. Fini,et al.  Matrix metalloproteinase-9 knockout confers resistance to corneal epithelial barrier disruption in experimental dry eye. , 2005, The American journal of pathology.

[49]  S. Pflugfelder.  Anti-inflammatory therapy of dry eye. , 2003, The ocular surface.